Scientific deep-dive
Melanotan and the Approved Drug It Is Not
An approved melanocortin-1 receptor agonist exists — afamelanotide, for preventing phototoxic pain in erythropoietic protoporphyria, given as a 16 mg implant under supervision. Melanotan sold for cosmetic tanning is not that drug.
There is an approved melanocortin‑1 receptor agonist. It is called afamelanotide, it went through phase 3 trials, and it is approved in the EU for one thing: preventing phototoxicity in adults with erythropoietic protoporphyria, a rare disorder in which sunlight causes pain. It is given as a biodegradable controlled-release implant containing 16 mg, under medical supervision.[1] Melanotan sold online for cosmetic tanning is not that drug, and the difference is the whole point.
What the approved one is for
Erythropoietic protoporphyria is a genetic condition in which exposure to light causes burning pain. In the phase 3 trial CUV039, afamelanotide improved light tolerance: patients spent more time in direct sunlight without pain, and it took longer for the first symptoms of phototoxicity to appear under a standardized light source. It was generally well tolerated, with no drug-related serious adverse events reported; common reactions were headache and implant-site reactions.[1]
Read what that indication actually is. The drug is approved to let people with a painful genetic photosensitivity disorder go outside. It is not approved to make anyone browner, and the trials measured pain-free time in sunlight, not appearance.
The four differences that matter
| Afamelanotide | Melanotan sold online | |
|---|---|---|
| Regulatory status | Approved (EU) for a named condition | Unapproved research chemical |
| Purpose | Preventing phototoxic pain in EPP | Cosmetic tanning |
| Form and dose | 16 mg controlled-release implant | Self-injected, dose set by the buyer |
| Oversight | Prescribed and administered clinically | None |
What we are not claiming, and why
Melanotan is frequently discussed in connection with changing moles and with melanoma. There is published case-report literature on that association. We looked at the most-cited example and its record carries no abstract we could read — a title and errata only. Rather than cite a paper we could not read and let you assume we had checked its contents, we are telling you the position: we did not verify those case details, so we are not building a claim on them.
What can be said without that literature is enough to act on. A compound that stimulates melanocytes, taken at an unmeasured dose, without supervision, for a cosmetic purpose, by people who are by definition seeking more pigment change than their skin produces on its own, is not a situation in which anyone is monitoring their moles. That is a reason for caution regardless of what any individual case report says.
- Melanotan is not approved anywhere for cosmetic tanning.
- Products sold under the name are research chemicals with no identity, purity or dose guarantee.
- The existence of an approved melanocortin agonist for a rare photosensitivity disorder is not evidence for an unapproved analog used cosmetically.
- ⚠ Any new, changing or asymmetric mole is worth showing to a doctor, and more so if you are using something that acts on melanocytes.
For the regulatory position on research-use peptides generally, see what FDA actually said about BPC-157. The peptides this register profiles in full are at /peptides.
Frequently Asked Questions
References
- 1.Kim ES, Garnock-Jones KP. Afamelanotide: A Review in Erythropoietic Protoporphyria American Journal of Clinical Dermatology. 2016. PMID: 26979527.
Related research
DSIP: A Sleep Peptide Named in 1977, With No Known Receptor
Delta sleep-inducing peptide was isolated in 1977 and named for what researchers hoped it did. A review of the field states the sleep hypothesis is extremely poorly documented and weak, and that no gene, protein or receptor has been isolated.
4 min read
Elamipretide (SS-31): The Phase 3 Trial That Missed Both Endpoints
Elamipretide has what almost no research-use peptide has — a completed pivotal phase 3 trial in 218 people. It missed both primary endpoints, with a six-minute walk difference of -3.2 meters and a p value of 0.69.
5 min read
LL-37: Thousands of Papers, No Human Trials
LL-37 is the body's own cathelicidin and the subject of thousands of papers. Read what they are and it is structural biology, cell culture and mice — including a wound-healing study in diabetic mice. We found no human clinical trial.
5 min read
MK-677: A Real Trial in Eight People, and a Liver Report
A 1998 randomized crossover trial found MK-677 reversed diet-induced protein catabolism, moving nitrogen balance from -2.67 to +0.31 g/day. It enrolled eight people and measured a proxy. A 2025 case report describes liver injury after two months of use.
5 min read
NAD+ Injections: What the Evidence Shows
A 2026 systematic review screened 113 studies and found no outcomes trials of injected NAD+ for anti-aging or wellness. It is the most common add-on in our 560-seller register, offered by 142 of them.
7 min read
Selank: Real Clinical Trials, One Country, No Replication
Selank was tested against a benzodiazepine in 62 patients with generalized anxiety disorder and reported similar anxiolytic effects. The study is from 2008, published in Russian, and has never been independently replicated.
5 min read
Where to get GLP-1 online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
HumeCare+
An oral route if you will not self-inject
Pricing Compare
Get started →Care Bare Rx
Knowing which pharmacy fills the vial — it names Belmar Pharmacy
Pricing Compare
Get started →Enhance MD
Knowing which pharmacy fills the vial — it names Tru Meds Rx
Pricing Compare
Get started →